Modified natural killer cells and natural killer cell lines having increased cytotoxicity

Inventors

O'Dwyer, Michael

Assignees

Onk Therapeutics Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10034925-B2

Patent

Publication Date

2018-07-31

Expiration Date


Abstract

NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to remove checkpoint inhibitory receptor expression and/or add mutant (variant) TRAIL ligand expression.

Core Innovation

The invention relates to natural killer (NK) cells and NK cell lines modified to increase cytotoxicity against DR5-expressing and/or DR5-inducible blood cancers. The modification comprises expressing a TRAIL variant with increased affinity for a DR5 TRAIL receptor compared to wildtype TRAIL, and the TRAIL variant comprises mutations D269H and E195R.

In certain embodiments, the TRAIL variant exhibits reduced affinity for decoy TRAIL receptors DcR1 and DcR2. The invention further describes combinations in which inhibitory checkpoint receptor function is reduced or removed in NK cells, including checkpoint inhibitory receptors such as CD96 (TACTILE), CD152 (CTLA4), CD223 (LAG-3), CD279 (PD-1), CD328 (SIGLEC7), SIGLEC9, TIGIT, and TIM-3, including via disruption of SHP-1/SHP-2/SHIP pathway components.

The invention also describes treating DR5-expressing and/or DR5-inducible blood cancers by administering the modified NK cells or NK cell lines. Additional optional aspects described include DR5 upregulation in tumors using a proteasome inhibitor such as bortezomib, and integration with CAR and/or Fc receptor expression together with bone-marrow homing features.

Claims Coverage

The independent claim covers a method of treating a DR5-expressing and/or DR5-inducible blood cancer by administering an NK cell or NK cell line engineered to express a TRAIL variant that preferentially binds DR5, with the TRAIL variant specified as containing mutations D269H and E195R. Dependent claims further refine the decoy-receptor affinity behavior, optional combination with bortezomib, selection of checkpoint inhibitory receptors, and some cancer- and targeting-specific embodiments.

DR5-preferring TRAIL variant expressing modified NK cells

Administering to treat a DR5-expressing and/or DR5-inducible blood cancer a natural killer (NK) cell or NK cell line modified to express a TRAIL variant having increased affinity for a DR5 TRAIL receptor compared to wildtype TRAIL, wherein the TRAIL variant comprises mutations D269H and E195R.

Reduced affinity for decoy TRAIL receptors

The TRAIL variant further provides reduced affinity for a decoy TRAIL receptor.

Combination with bortezomib to support DR5 inducibility

The method further comprises administering an effective amount of bortezomib as the proteasome inhibitor.

Checkpoint inhibitory receptor functional reduction

A checkpoint inhibitory receptor is one of CD96 (TACTILE), CD152 (CTLA4), CD223 (LAG-3), CD279 (PD-1), CD328 (SIGLEC7), SIGLEC9, TIGIT, or TIM-3.

Use of KHYG-1 NK cell line for specific indications

The method uses an NK cell line that is a KHYG-1 cell line to treat chronic myeloid leukemia or multiple myeloma.

Targeting the bone marrow

An NK cell or NK cell line targets the bone marrow.

Overall, the claim coverage centers on using modified NK cells or NK cell lines that express a DR5-binding TRAIL variant containing D269H and E195R, with dependent features further specifying decoy-receptor affinity reduction, optional bortezomib co-administration, checkpoint inhibitory receptor selection for functional reduction, and embodiments tying the NK platform to KHYG-1 and bone-marrow targeting.

Stated Advantages

Increased cytotoxicity against DR5-expressing and/or DR5-inducible blood cancers.

Documented Applications

Treating a DR5-expressing and/or DR5-inducible blood cancer in an individual in need thereof.

Treating chronic myeloid leukemia or multiple myeloma using an NK cell line that is a KHYG-1 cell line.

Targeting the bone marrow for NK cell or NK cell line therapy.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.